247 related articles for article (PubMed ID: 31607268)
1. Infliximab for pediatric patients with ulcerative colitis: a phase 3, open-label, uncontrolled, multicenter trial in Japan.
Tajiri H; Arai K; Kagimoto S; Kunisaki R; Hida N; Sato N; Yamada H; Nagano M; Susuta Y; Ozaki K; Kondo K; Hibi T
BMC Pediatr; 2019 Oct; 19(1):351. PubMed ID: 31607268
[TBL] [Abstract][Full Text] [Related]
2. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
Kobayashi T; Suzuki Y; Motoya S; Hirai F; Ogata H; Ito H; Sato N; Ozaki K; Watanabe M; Hibi T
J Gastroenterol; 2016 Mar; 51(3):241-51. PubMed ID: 26162647
[TBL] [Abstract][Full Text] [Related]
3. Infliximab for pediatric patients with Crohn's disease: A Phase 3, open-label, uncontrolled, multicenter trial in Japan.
Tajiri H; Motoya S; Kinjo F; Maemoto A; Matsumoto T; Sato N; Yamada H; Nagano M; Susuta Y; Ozaki K; Kondo K; Hibi T
PLoS One; 2018; 13(8):e0201956. PubMed ID: 30114224
[TBL] [Abstract][Full Text] [Related]
4. Histological healing after infliximab induction therapy in children with ulcerative colitis.
Wiernicka A; Szymanska S; Cielecka-Kuszyk J; Dadalski M; Kierkus J
World J Gastroenterol; 2015 Oct; 21(37):10654-61. PubMed ID: 26457025
[TBL] [Abstract][Full Text] [Related]
5. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
Iwasa R; Yamada A; Sono K; Furukawa R; Takeuchi K; Suzuki Y
BMC Gastroenterol; 2015 Aug; 15():103. PubMed ID: 26271624
[TBL] [Abstract][Full Text] [Related]
6. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.
Moore H; Dolce P; Devas N; Baldassano R; Martinelli M
United European Gastroenterol J; 2020 May; 8(4):425-435. PubMed ID: 32213038
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of infliximab in treating patients with ulcerative colitis: experiences from a single medical center in southern China.
Zhou YL; Xie S; Wang P; Zhang T; Lin MY; Tan JS; Zhi FC; Jiang B; Chen Y
J Dig Dis; 2014 Sep; 15(9):483-90. PubMed ID: 24828856
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Cohort Study of Infliximab Pharmacokinetics and Therapy Response in Pediatric Acute Severe Ulcerative Colitis.
Whaley KG; Xiong Y; Karns R; Hyams JS; Kugathasan S; Boyle BM; Walters TD; Kelsen J; LeLeiko N; Shapiro J; Waddell A; Fox S; Bezold R; Bruns S; Widing R; Haberman Y; Collins MH; Mizuno T; Minar P; D'Haens GR; Denson LA; Vinks AA; Rosen MJ
Clin Gastroenterol Hepatol; 2023 May; 21(5):1338-1347. PubMed ID: 36031093
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of vedolizumab and infliximab in biologic-naïve patients with moderate-to-severe ulcerative colitis: A multicenter, retrospective cohort study.
Meng RP; Huang BB; Wei YL; Lyu L; Yang H; Liu C; Zhou HL; Liao XP; Zhou JY; Xie X
J Dig Dis; 2024 Apr; 25(4):230-237. PubMed ID: 38764418
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of infliximab in children with moderate-to-severe ulcerative colitis: results from a randomized, multicenter, open-label, phase 3 study.
Adedokun OJ; Xu Z; Padgett L; Blank M; Johanns J; Griffiths A; Ford J; Zhou H; Guzzo C; Davis HM; Hyams J
Inflamm Bowel Dis; 2013 Dec; 19(13):2753-62. PubMed ID: 24193155
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations after switching from originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease (SECURE): an open-label, multicentre, phase 4 non-inferiority trial.
Strik AS; van de Vrie W; Bloemsaat-Minekus JPJ; Nurmohamed M; Bossuyt PJJ; Bodelier A; Rispens T; van Megen YJB; D'Haens GR;
Lancet Gastroenterol Hepatol; 2018 Jun; 3(6):404-412. PubMed ID: 29606564
[TBL] [Abstract][Full Text] [Related]
12. Induction and maintenance infliximab therapy in children with moderate to severe ulcerative colitis: Retrospective, multicenter study.
Iwańczak BM; Kierkuś J; Ryżko J; Szczepanik M; Więcek S; Czaja-Bulsa G; Kacperska M; Korczowski B; Maślana J; Iwańczak F
Adv Clin Exp Med; 2017; 26(1):57-61. PubMed ID: 28397433
[TBL] [Abstract][Full Text] [Related]
13. Accelerated Clearance of Infliximab is Associated With Treatment Failure in Patients With Corticosteroid-Refractory Acute Ulcerative Colitis.
Kevans D; Murthy S; Mould DR; Silverberg MS
J Crohns Colitis; 2018 May; 12(6):662-669. PubMed ID: 29659758
[TBL] [Abstract][Full Text] [Related]
14. Prognosis of pediatric ulcerative colitis after infliximab failure: A multicenter registry-based cohort study.
Nambu R; Kudo T; Tachibana N; Shimizu H; Mizuochi T; Kato S; Inoue M; Kumagai H; Ishige T; Kunisaki R; Noguchi A; Yodoshi T; Hagiwara SI; Nishimata S; Kakuta F; Saito T; Iwama I; Hirano Y; Shimizu T; Arai K;
J Gastroenterol Hepatol; 2024 Feb; 39(2):312-318. PubMed ID: 38058020
[TBL] [Abstract][Full Text] [Related]
15. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
[TBL] [Abstract][Full Text] [Related]
16. Disease activity, ANCA, and IL23R genotype status determine early response to infliximab in patients with ulcerative colitis.
Jürgens M; Laubender RP; Hartl F; Weidinger M; Seiderer J; Wagner J; Wetzke M; Beigel F; Pfennig S; Stallhofer J; Schnitzler F; Tillack C; Lohse P; Göke B; Glas J; Ochsenkühn T; Brand S
Am J Gastroenterol; 2010 Aug; 105(8):1811-9. PubMed ID: 20197757
[TBL] [Abstract][Full Text] [Related]
17. A comparison of short-term therapeutic efficacy between infliximab and tacrolimus for moderate to severe ulcerative colitis.
Yamagami H; Nishida Y; Nagami Y; Hosomi S; Yukawa T; Otani K; Tanaka F; Taira K; Kamata N; Tanigawa T; Shiba M; Watanabe T; Fujiwara Y
Rom J Intern Med; 2017 Sep; 55(3):151-157. PubMed ID: 28222041
[TBL] [Abstract][Full Text] [Related]
18. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
[TBL] [Abstract][Full Text] [Related]
19. High-dose infliximab for treatment of pediatric ulcerative colitis: a survey of clinical practice.
Nattiv R; Wojcicki JM; Garnett EA; Gupta N; Heyman MB
World J Gastroenterol; 2012 Mar; 18(11):1229-34. PubMed ID: 22468086
[TBL] [Abstract][Full Text] [Related]
20. [Evaluation of efficacy and comparative frequency of adverse events in patients with ulcerative colitis receiving the original infliximab and its biosimilar. One year of observation].
Knyazev OV; Shkurko TV; Kagramanova AV; Lishchinskaya AA; Zvyaglova MY; Korneeva IA; Babayan AF; Parfenov AI
Ter Arkh; 2019 Aug; 91(8):41-46. PubMed ID: 32598753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
